ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision

iSpecimen gained more than 37% in overnight trading despite no identified company-specific news, highlighting speculative momentum in small-cap biotech. Genelux is approaching a potential clinical catalyst for lead candidate Olvi-Vec in the coming months, while the article also flags Anixa Biosciences among biotech names to watch. The developments are likely relevant primarily to individual biotech stocks rather than the broader market.